Philippe Backeljauw, MD
Disclosures: Consultant/Advisor-Novo Nordisk|Research Support-Novo Nordisk|Research Support-Ipsen|Research Support-Sandoz|Research Support-Opko

 

Philippe F. Backeljauw, USA

 

Philippe F. Backeljauw is Professor of Clinical Pediatrics at the University of Cincinnati College of Medicine, USA. He practises pediatric endocrinology at Cincinnati Children’s Hospital Medical Center, where he has been on the faculty since 1999. He is Medical Director of the Cincinnati Center for Pediatric and Adult Turner Syndrome Care, the Pediatric Endocrinology Fellowship Program Director, and he is a member of the Cincinnati Center for Growth Disorders.

Professor Backeljauw is engaged in clinical research related to growth disorders and Turner syndrome. He is a collaborator in several ongoing studies, including several projects related to Turner syndrome and its comorbidities. The Cincinnati Center for Pediatric and Adult Turner Syndrome Care is perhaps the largest Turner syndrome center in the United States and provides comprehensive clinical care to patients with Turner syndrome across their lifespan. In 2017 he was the senior author on the new guidelines for clinical care for girls and women with Turner syndrome, after organizing (with Claus Gravholt) an international society-sponsored consensus meeting for this.

Dr. Backeljauw has published more than 90 peer-reviewed manuscripts and more than 100 abstracts, 17 textbook chapters, and has given more than 90 invited presentations at national and international meetings. As major scientific contribution one may include that he was the PI (together with Louis Underwood and Steven Chernausek) on the long-term studies with patients with growth hormone insensitivity syndrome (growth hormone resistance) between 1992 and 2013. He was the first in the world to treat these growth hormone resistant patients long term, and the data from these studies eventually brought recombinant human IGF-1 to USFDA and EMA approval.